<p>Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses the role of abiraterone acetate in the treatment of patients with prostate cancer, and the questions that remain about its use.</p>
Raoul Tibes, MD, PhD, physician-scientist at the University Hospital Head Myeloid Malignancies, Department of Internal Medicine II at the University Hospital in Würzburg, and adjunct consultant at Mayo Clinic, discusses the role of FLT3 inhibitors in the treatment of patients with acute myeloid leukemia.
Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, gives an overview of the JAVELIN trial in gastric cancer. He also discusses the safety profile of avelumab.
Stanley Yap, MD, assistant professor, urologic oncology, UC Davis Comprehensive Cancer Center, discusses needed improvements and next steps in neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti-PD-1 therapy in renal cell carcinoma.
Fred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that highlights the optimal use of the identification of genetic risk factors in prostate cancer, as well as the biology of developing prostate cancer.
David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the important considerations and challenges in using immune checkpoint inhibitors to treat patients with glioblastoma.
Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses the significance of the ipilimumab/nivolumab findings from the CheckMate-069 trial for melanoma.
Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses the potential role that PD-1 inhibitors may play in the treatment of liver cancer.
Christopher Heery, MD, medical oncologist, National Cancer Institute, discusses the potential underlying benefits of combination therapy in the treatment of patients with gastrointestinal (GI) cancers.
Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the use of natural language processing in the diagnosis of lung cancer.
Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor in the Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the ideal patient population that can potentially benefit from the use of nivolumab in the treatment of non-small cell lung cancer.
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the prospective benefits of the TAPUR clinical trial, which is being conducted by ASCO.
Ghassan Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses the important role that locoregional therapy plays in the treatment of liver cancer.
Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the major impact that regorafenib and sorafenib will have for the treatment of liver cancer.
Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses two ongoing trials utilizing multi-gene panels to uncover previously undetected risks in patients with breast and ovarian cancer.
Anas Younes, MD, medical oncologist at Memorial Sloan Kettering Cancer Center in New York, discusses the potential impact of CheckMate-205 nivolumab as a treatment for patients with Hodgkin lymphoma.
Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy as a treatment for patients with colorectal cancer.
Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute, discusses the challenges with finding biomarkers for immunotherapy agents.
Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses how the Cologuard test compares with other screening tools for colorectal cancer.
Antoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses how to appropriately sequence therapies for patients with melanoma.
Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses what is on the horizon for the treatment landscape of bladder cancer.
Walter Weder, MD, University Hospital, Division of Thoracic Surgery, discusses challenges in mesothelioma treatment and why specialized centers are best for the patient.
Brian A. Van Tine, MD, PhD, assistant professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses the importance of understanding molecular subtypes of sarcoma.
Todd Murphree, PharmD, pharmacist, Clearview Cancer Institute, discusses measuring the quality and value of having oncology pharmacy accreditation.
Sue Naeyaert, senior director of Biosimilars Policy, EMD Serono, discusses the long-term impact that biosimilars could potentially have on the field of oncology.
John L. Marshall, MD, chief of the Division of Hematology/Oncology at Georgetown University Hospital, discusses the challenges faced with treating patients who have gastrointestinal cancers and the significance of molecular profiling.
Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and Clinical Director Jefferson Sidney Kimmel Cancer Network, shares insight on genomic markers in patients with prostate cancer.
Wouter W. de Herder, MD, PhD, professor of Endocrine Oncology, Erasmus MC, discusses the use of somatostatin analogs in patients with neuroendocrine tumors, as well as significant clinical trials investigating these agents.
Morie A. Gertz, MD, chair, Internal Medicine, Mayo Clinic, discusses the treatment options available for patients with Waldenstrom's Macroglobulinemia and the ongoing clinical trials taking place in the field.